RPRX Company Profile and Key Details

Royalty Pharma plc (NASDAQ:RPRX) closed at $63.96 USD, gaining $0.08 (0.13%) from the previous close of $63.88. The stock is currently trading near its 52-week high $34.08 and $64.38. With a market capitalization of about $28.35 billion, Royalty Pharma plc is classified as a large-cap and shows lower-than-market volatility (beta ~0.42). Key stats such as the average daily volume over the past year has been around 3.01 million shares, in line with its 52-week average. Headquartered in New York, NY, Royalty Pharma plc operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Pablo Legorreta, the company employs approximately 100 people and listed since June 16, 2020. Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.

Short-term trend indicators are bearishly aligned (SMA20 2.49%, SMA50 9.41%, SMA200 20.66%). The stock’s 14-day RSI is 71.97 (overbought), while the ATR of 0.83 points to moderate volatility. The stock remains sitting in the mid-range of its 52-week band, trading -1.69% below its high and over 52.93% above its low. Average 10-day trading volume of 2.61 million shares is below the 3-month average of 3.03 million, indicating normal recent market interest.

Royalty Pharma plc last paid a dividend of 0.93 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $94.01. This means the shares are trading below this model’s fair value.

Royalty Pharma plc generated EPS of $1.78 over the past year. Five-year average earnings growth is -7.26%. Wall Street analysts project EPS growth of 7.4% annually over the next five years. The latest quarter delivered EPS of $1.32. The next quarter is forecast at $1.07. Next year's EPS is expected at -$6.32. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $66.00 to $42.00. The high target offers 3.19% upside. The low target suggests -34.33% downside. The mean target is $55.56. This offers -13.13% upside. Royalty Pharma plc earnings surprise history is a mixed track record. The quarter that ended August 05, 2026, missed forecasts by 3.94%. The prior quarter beat by -56.56%. Over the last six quarters, Apple has recorded several small beats. These include 11.23% in May 08, 2025.

Royalty Pharma plc has 445.28 million shares outstanding. The public float is 415.52 million shares, elevated short interest at 2.43% of float. This equals 10.67 million shares. The short ratio is 3.92 days. Institutional investors hold 93.36% of the float. Insiders own 6.49%. GG 1978 SICAF SIF S.A. holds 22.08 million shares, GG 1978 SICAF SIF S.A. - GG Strategic has 21.43 million shares and Giuliani Mario Germano has 7.80 million shares. Over the past six months, insider transactions show net selling. They sold 383.35 thousand shares across 10 transactions.

Royalty Pharma plc trades at a P/E ratio of 26.5, slightly below the S&P 500 average, with a price-to-sales ratio of 11.16 and a price-to-book ratio of 4.16 trading at moderately above to book value. The P/FCF stands at 9.51, also above market averages.

Our AI price prediction model suggests that Royalty Pharma plc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.03%, with price expected at $65.26 by September 18, 2026, within a range of $63.85 to $66.65 3-Month Outlook: Projected rise of 29.08%, reaching $82.56 by December 03, 2026, with a range of $81.60 to $83.77. 1-Year Outlook: Projected gain of 13.57%, with price at $72.64 by September 03, 2027, within a range of $70.95 to $74.91.

Royalty Pharma plc (NASDAQ:RPRX) shares are flat 1.16% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Royalty Pharma plc trading at a premium to the broader market with a P/E of 26.5. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $52.48, suggesting -17.95% downside. Our AI forecast model points to short-term strength (2.03% over two weeks), a medium-term rise (29.08% over three months), and a longer-term gain (13.57% over one year), with expected trading ranges indicating moderate volatility.